Leerink Partnrs Weighs in on COGT Q1 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the technology company will post earnings of ($0.57) per share for the quarter. The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.54) EPS, Q4 2025 earnings at ($0.55) EPS and FY2027 earnings at $0.72 EPS.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings data on Tuesday, November 12th. The technology company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.07). During the same quarter in the prior year, the company posted ($0.64) EPS.

A number of other equities research analysts have also recently issued reports on COGT. HC Wainwright decreased their price objective on shares of Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Needham & Company LLC lowered Cogent Biosciences from a “buy” rating to a “hold” rating in a report on Wednesday, December 11th. Wedbush reissued a “neutral” rating and set a $11.00 target price on shares of Cogent Biosciences in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Cogent Biosciences from $19.00 to $21.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $14.33.

Cogent Biosciences Price Performance

NASDAQ:COGT opened at $9.17 on Friday. The business’s fifty day moving average price is $8.44 and its 200 day moving average price is $9.67. Cogent Biosciences has a 1-year low of $5.37 and a 1-year high of $12.61.

Institutional Trading of Cogent Biosciences

Several institutional investors have recently added to or reduced their stakes in COGT. SG Americas Securities LLC grew its stake in shares of Cogent Biosciences by 2,865.3% in the fourth quarter. SG Americas Securities LLC now owns 964,712 shares of the technology company’s stock valued at $7,525,000 after acquiring an additional 932,179 shares in the last quarter. FMR LLC grew its position in shares of Cogent Biosciences by 8.1% during the 3rd quarter. FMR LLC now owns 8,319,411 shares of the technology company’s stock worth $89,850,000 after purchasing an additional 625,743 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Cogent Biosciences in the third quarter valued at approximately $6,019,000. Geode Capital Management LLC boosted its stake in shares of Cogent Biosciences by 15.1% in the third quarter. Geode Capital Management LLC now owns 2,280,793 shares of the technology company’s stock valued at $24,638,000 after buying an additional 300,062 shares during the period. Finally, Bank of Montreal Can bought a new stake in shares of Cogent Biosciences in the third quarter valued at approximately $3,135,000.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.